Malignant clonal evolution drives multiple myeloma cellular ecological diversity and microenvironment reprogramming

Mol Cancer. 2022 Sep 22;21(1):182. doi: 10.1186/s12943-022-01648-z.

Abstract

Background: Multiple myeloma (MM) is a heterogeneous disease with different patterns of clonal evolution and a complex tumor microenvironment, representing a challenge for clinicians and pathologists to understand and dissect the contribution and impact of polyclonality on tumor progression.

Methods: In this study, we established a global cell ecological landscape of the bone marrow (BM) from MM patients, combining single-cell RNA sequencing and single-molecule long-read genome sequencing data.

Results: The malignant mutation event was localized to the tumor cell clusters with shared mutation of ANK1 and IFITM2 in all malignant subpopulations of all MM patients. Therefore, these two variants occur in the early stage of malignant clonal origin to mediate the malignant transformation of proplasmacytes or plasmacytes to MM cells. Tumor cell stemness index score and pseudo-sequential clonal evolution analysis can be used to divide the evolution model of MM into two clonal origins: types I and IX. Notably, clonal evolution and the tumor microenvironment showed an interactive relationship, in which the evolution process is not only selected by but also reacts to the microenvironment; thus, vesicle secretion enriches immune cells with malignant-labeled mRNA for depletion. Interestingly, microenvironmental modification exhibited significant heterogeneity among patients.

Conclusions: This characterization of the malignant clonal evolution pattern of MM at the single-cell level provides a theoretical basis and scientific evidence for a personalized precision therapy strategy and further development of a potential new adjuvant strategy combining epigenetic agent and immune checkpoint blockade.

Keywords: Cell heterogeneity; Cellular ecological diversity; Malignant clonal evolution; Microenvironment reprogramming; Multiple myeloma.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Bone Marrow / pathology
  • Clonal Evolution / genetics
  • Humans
  • Immune Checkpoint Inhibitors
  • Membrane Proteins / genetics
  • Multiple Myeloma* / pathology
  • RNA, Messenger
  • Tumor Microenvironment / genetics

Substances

  • IFITM2 protein, human
  • Immune Checkpoint Inhibitors
  • Membrane Proteins
  • RNA, Messenger